166 filings
Page 2 of 9
8-K
2k4uxd5d3uavszpfdej
12 Oct 23
Material Modifications to Rights of Security Holders
4:01pm
8-K
89dt6yhivjf2m5ucs
18 Sep 23
Departure of Directors or Certain Officers
5:03pm
8-K
1vit76iauu luy
11 Aug 23
T2 Biosystems Announces Second Quarter 2023 Financial Results
4:00pm
8-K
mzh wdg6ewjr
9 Aug 23
Regulation FD Disclosure
4:10pm
8-K
hr5kzz
31 Jul 23
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
9:11am
8-K
dly5kj0gyj9bf5 hi
20 Jul 23
T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
8:30am
8-K
fj4lsy4
12 Jul 23
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
8:05am
8-K
yye1990z9j92vzrzqjqz
6 Jul 23
Entry into a Material Definitive Agreement
8:08am
8-K
ngat3czlrkx4
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:01pm
8-K
e7o5 oi7vqxodw
9 Jun 23
Regulation FD Disclosure
8:45am
8-K
ogq x4d6s7pq
5 Jun 23
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
9:00am
8-K
nu7mvk
30 May 23
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
9:01am
8-K
in3l0d5p ve1ei8m
25 May 23
T2 Biosystems Announces First Quarter 2023 Financial Results
4:55pm
8-K
afyi8v1a1b
23 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:13pm
8-K
wpeshdpn
31 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:00pm
8-K
3qq6z
16 Mar 23
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
4:01pm
8-K
ad7p s8igyn3
16 Feb 23
Other Events
4:17pm
8-K
g2876
13 Feb 23
Other Events
4:05pm
8-K
nivzzf7y
23 Jan 23
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
5:11pm
8-K
4b8ybjaddeun5dtijlh
25 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm